Related Experiment Videos
[Medical treatment of arteriosclerosis obliterans (ASO)]
1National Cardiovascular Center, Department of Cardiovascular Medicine, Suita, Japan.
Insights
Managing Atherosclerosis (ASO) involves controlling risk factors like smoking and diabetes, treating leg ischemia, and preventing vascular events. Antiplatelet therapy is key for symptom relief and reducing risks like heart attack and stroke.
Area of Science:
- Vascular Medicine
- Cardiology
- Preventive Medicine
Context:
- Atherosclerosis (ASO) significantly impacts patient health, leading to leg ischemia and other organ damage.
- Key risk factors include cigarette smoking, diabetes mellitus, and hyperlipidemia.
- Effective management requires a multi-faceted approach addressing risk factors and ischemic complications.
Purpose:
- To outline a comprehensive medical treatment strategy for Atherosclerosis (ASO).
- To emphasize risk factor modification, symptom management, and prevention of severe vascular events.
Summary:
- Treatment involves minimizing atherosclerosis risk factors (smoking cessation, controlling diabetes and hyperlipidemia), managing leg ischemia with therapies like antiplatelet and vasodilatory drugs, and addressing other ischemic organs.
- Daily physical exercise, especially when combined with drug therapy, improves walking distance for intermittent claudication.
- Antiplatelet therapy plays a crucial role in symptom relief and significantly reduces the incidence of vascular events (myocardial infarction, stroke) and vascular death.
Impact:
- Provides a strategic framework for clinicians treating Atherosclerosis (ASO).
- Highlights the dual benefit of antiplatelet therapy in improving quality of life and long-term prognosis.
- Underscores the importance of lifestyle modifications and pharmacotherapy in ASO management.
Abstract:
The medical treatment of ASO should be approached in three ways. The first should be to minimize the risk factors of "atherosclerosis", the second should be the treatment of leg ischemia, and the third should be the management of other ischemic organs. Among the risk factors involved, cigarette smoking, diabetes mellitus and hyperlipidemia are frequently evident. Smoking must be given up and the other diseases should be controlled by diet, exercise and drug therapy respectively. In order to relieve symptoms such as cold sensation and intermittent claudication, drug therapy such as antiplatelet therapy and vasodilatory drugs are useful in the treatment of some patients with ASO. Daily physical exercises are also effective in extending the walking distance in patients with intermittent claudication. This exercise is even more effective when it is combined with drug therapy. The prevention of vascular events such as myocardial infarction and stroke and the prevention of vascular death are very important in patients with ASO. It can therefore be concluded that antiplatelet therapy is not only effective in relieving symptoms, but also in reducing the incidence of vascular events and death.